Skip to main content

Table 4 Summary of second-line treatments

From: Trastuzumab with either docetaxel or vinorelbine as first-line treatment for patients with HER2-positive advanced breast cancer: a retrospective comparison

  Initial Docetaxel + T Initial Vinorelbine + T
Treatment N 80 (T)1 N 57 (T)1
Vinorelbine-based 31 (15) 3 (1)
Paclitaxel-based 1 (0) 11 (7)
Docetaxel-based 3 (2) 6 (3)
Capecitabine-based 6 (1) 12 (4)
Trastuzumab2 10 6
Anthracycline-based 6 (0) 3 (0)
Endocrine therapy 9 (5) 1 (0)
Miscellaneous 3 (0) 7 (2)
Best supportive care 3 (0) 3 (0)
Treatment not detailed 8 5
  1. 1Number in parentheses indicate the number of patients who continued trastuzumab beyond disease progression in addition to chemotherapy or endocrine therapy
  2. 2Patients receiving trastuzumab alone had isolated central nervous system progression and were managed with radiation therapy.